Pfizer (PFE)
(Delayed Data from NYSE)
$26.32 USD
+0.06 (0.23%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $26.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Revenue: Primary Care: Worldwide
- 30,589.00
- 73,023.00
- 52,029.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Specialty Care: Worldwide
- 14,970.00
- 13,833.00
- 15,194.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Worldwide
- 11,627.00
- 12,132.00
- 12,333.00
- 10,867.00
- 9,014.00
- Revenue - Line of Business (LOBR)
- Revenues: Pfizer CentreOne: Worldwide
- 1,265.00
- 1,342.00
- 1,731.00
- 926.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Primary Care: Eliquis alliance revenues and direct sales: Worldwide
- 6,747.00
- 6,480.00
- 5,970.00
- 4,949.00
- 4,220.00
- Revenue - Line of Business (LOBR)
- Revenues: Primary Care: Prevnar family: Worldwide
- 6,440.00
- 6,337.00
- 5,272.00
- 5,850.00
- 5,847.00
- Revenue - Line of Business (LOBR)
- Revenues: Primary Care: Premarin family: Worldwide
- 397.00
- 455.00
- 563.00
- 680.00
- 734.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Vyndaqel family: Worldwide
- 3,321.00
- 2,447.00
- 2,015.00
- 1,288.00
- 473.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Xeljanz: Worldwide
- 1,703.00
- 1,796.00
- 2,455.00
- 2,437.00
- 2,242.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Enbrel: Worldwide
- 830.00
- 1,003.00
- 1,185.00
- 1,350.00
- 1,699.00
- Revenue - Line of Business (LOBR)
- Revenue: Business Innovation - Pfizer Ignite
- 44.00
- 7.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: FSME-IMMUN/TicoVac
- 268.00
- 200.00
- 185.00
- 196.00
- 220.00
- Revenue - Line of Business (LOBR)
- Revenue-Pharmaceutical: BMP2
- 338.00
- 277.00
- 266.00
- 274.00
- 287.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Genotropin: Worldwide
- 539.00
- 360.00
- 389.00
- 427.00
- 498.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Fragmin: Worldwide
- 238.00
- 269.00
- 305.00
- 252.00
- 253.00
- Revenue - Line of Business (LOBR)
- Revenue: Specialty Care: Oxbryta: Worldwide
- 328.00
- 73.00
- 0.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Oncology: Bavencio alliance revenues: Worldwide
- 190.00
- 271.00
- 56.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Primary Care - All Other Primary Care
- 1,777.00
- 1,932.00
- 1,967.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Ruxience
- 390.00
- 458.00
- 491.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Zirabev
- 424.00
- 562.00
- 444.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Braftovi
- 213.00
- 194.00
- 187.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Mektovi
- 174.00
- 176.00
- 155.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Besponsa
- 236.00
- 219.00
- 192.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Retacrit
- 340.00
- 394.00
- 444.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology -Trazimera
- 91.00
- 203.00
- 197.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Specialty Care - Ig Portfolio - US
- 584.00
- 491.00
- 119.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Specialty Care - Ig Portfolio
- 584.00
- 491.00
- 430.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: All other Anti-infectives
- 1,092.00
- 1,171.00
- 1,835.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: All other Specialty Care
- 2,244.00
- 2,350.00
- 2,830.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Primary Care: Paxlovid - Worldwide
- 1,279.00
- 18,933.00
- 76.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Specialty Care - Cibinqo
- 128.00
- 27.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Ibrance: Worldwide
- 4,753.00
- 5,120.00
- 5,437.00
- 5,392.00
- 4,961.00
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - Lorbrena
- 539.00
- 343.00
- 266.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Xalkori: Worldwide
- 374.00
- 465.00
- 493.00
- 544.00
- 530.00
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Inlyta: Worldwide
- 1,036.00
- 1,003.00
- 1,002.00
- 787.00
- 477.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Somavert: Worldwide
- 267.00
- 268.00
- 277.00
- 277.00
- 264.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Sulperazon: Worldwide
- 757.00
- 786.00
- 683.00
- 618.00
- 684.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Refacto AF/Xyntha: Worldwide
- 230.00
- 239.00
- 304.00
- 370.00
- 426.00
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Sutent: Worldwide
- 180.00
- 347.00
- 673.00
- 819.00
- 936.00
- Revenue - Line of Business (LOBR)
- Revenue-Pharmaceutical: Oncology-Aromasin
- 301.00
- 248.00
- 211.00
- 148.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Zithromax: Worldwide
- 406.00
- 331.00
- 278.00
- 276.00
- 336.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Vfend: Worldwide
- 187.00
- 225.00
- 267.00
- 270.00
- 346.00
- Revenue - Line of Business (LOBR)
- Revenue - Oncology: Medrol
- 339.00
- 328.00
- 432.00
- 402.00
- 469.00
- Revenue - Line of Business (LOBR)
- Pfizer Biopharma: Total
- 57,186.00
- 98,988.00
- 79,557.00
- 40,724.00
- --
- Revenue - Line of Business (LOBR)
- Revenues: Primary Care: Comirnaty direct sales and alliance revenues - Worldwide
- 11,220.00
- 37,806.00
- 36,781.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Primary Care: Nimenrix: Worldwide
- 179.00
- 268.00
- 48.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenue: Primary Care: Nurtec ODT/Vydura: Worldwide
- 928.00
- 213.00
- 0.00
- --
- --
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Bosulif: Worldwide
- 645.00
- 575.00
- 540.00
- 450.00
- 365.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: Inflectra: Worldwide
- 490.00
- 532.00
- 657.00
- 659.00
- 625.00
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Xtandi alliance revenues: Worldwide
- 1,191.00
- 1,198.00
- 1,185.00
- 1,024.00
- 838.00
- Revenue - Line of Business (LOBR)
- Revenues: Oncology: Xtandi alliance revenues: United States
- 1,191.00
- 1,198.00
- 1,185.00
- 1,024.00
- 838.00
- Revenue - Line of Business (LOBR)
- Revenues: Pharmaceutical: Oncology - All Other Oncology
- 433.00
- 357.00
- 238.00
- 137.00
- 470.00
- Revenue - Line of Business (LOBR)
- Revenues: Specialty Care: BeneFIX: Worldwide
- 424.00
- 425.00
- 438.00
- 454.00
- 488.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Total International
- 18,119.00
- 44,521.00
- 12,410.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: United States
- 12,470.00
- 28,503.00
- 3,815.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Nurtec ODT/Vydura: Total International
- 20.00
- 2.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Nurtec ODT/Vydura: United States
- 908.00
- 211.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Pfizer CentreOne: United States
- 345.00
- 390.00
- 524.00
- 400.00
- 437.00
- Revenue - Geographic (GEOR)
- Revenues: Pfizer CentreOne: Total International
- 920.00
- 952.00
- 1,206.00
- 526.00
- 374.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Comirnaty direct sales and alliance revenues: Total International
- 8,816.00
- 29,032.00
- 10,353.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Paxlovid: United States
- -1,289.00
- 10,514.00
- 76.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Paxlovid: Total International
- 2,568.00
- 8,419.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Primary Care: Eliquis alliance revenues and direct sales: United States
- 4,228.00
- 3,822.00
- 3,160.00
- 2,688.00
- 2,343.00
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - All other Specialty Care-International
- 965.00
- 999.00
- 1,223.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Specialty Care-US
- 6,601.00
- 5,659.00
- 6,156.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Specialty Care-International
- 8,370.00
- 8,174.00
- 9,038.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Zirabev- US
- 304.00
- 413.00
- 246.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Zirabev - ROW
- 119.00
- 149.00
- 197.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Ruxience - US
- 308.00
- 403.00
- 450.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Ruxience - ROW
- 82.00
- 55.00
- 41.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Retacrit - US
- 259.00
- 312.00
- 344.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical- Oncology- Retacrit - ROW
- 81.00
- 82.00
- 100.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Lorbrena - US
- 224.00
- 177.00
- 141.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Lorbrena- ROW
- 314.00
- 166.00
- 125.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Besponsa - US
- 134.00
- 126.00
- 115.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Besponsa - ROW
- 102.00
- 93.00
- 77.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Braftovi - US
- 203.00
- 191.00
- 187.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Braftovi - ROW
- 10.00
- 3.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Trazimera - US
- -8.00
- 106.00
- 98.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Trazimera - ROW
- 99.00
- 97.00
- 99.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Mektovi - US
- 171.00
- 175.00
- 155.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology-Mektovi - ROW
- 3.00
- 1.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Geographic Revenue: United States
- 27,088.00
- 42,473.00
- 29,746.00
- 21,455.00
- 20,326.00
- Revenue - Geographic (GEOR)
- Geographic Revenue: Total International
- 31,408.00
- 57,857.00
- 51,542.00
- 20,196.00
- 20,579.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Comirnaty direct sales and alliance revenues: United States
- 2,404.00
- 8,537.00
- 7,652.00
- 5,418.00
- 4,648.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: BeneFIX: Total International
- 200.00
- 191.00
- 207.00
- 215.00
- 246.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: BeneFIX: United States
- 225.00
- 235.00
- 230.00
- 239.00
- 242.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: BMP2-United States
- 338.00
- 277.00
- 266.00
- 274.00
- 287.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Enbrel: Total International
- 830.00
- 1,003.00
- 1,185.00
- 1,350.00
- 1,699.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Genotropin: Total International
- 386.00
- 292.00
- 310.00
- 299.00
- 405.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Genotropin: United States
- 153.00
- 68.00
- 79.00
- 128.00
- 93.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Fragmin-International
- 236.00
- 264.00
- 300.00
- 245.00
- 244.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Fragmin-United States
- 2.00
- 4.00
- 5.00
- 7.00
- 9.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Infectious & Respiratory diseases-Vfend -United States
- 6.00
- 5.00
- 8.00
- 20.00
- 13.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Infectious & Respiratory diseases-Vfend-International
- 181.00
- 221.00
- 260.00
- 250.00
- 333.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Infectious & Respiratory diseases-Zithromax /Zmax-International
- 404.00
- 328.00
- 278.00
- 271.00
- 338.00
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Infectious & Respiratory diseases-Zithromax /Zmax-United States [$M]
- 1.00
- 2.00
- 1.00
- 5.00
- -1.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical-Medrol: International
- 206.00
- 196.00
- 251.00
- 204.00
- 221.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical-Medrol: United States
- 132.00
- 132.00
- 181.00
- 198.00
- 248.00
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Oncology-Aromasin-International
- 298.00
- 246.00
- 208.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue-Pharmaceutical: Oncology-Aromasin-United States
- 2.00
- 2.00
- 3.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Sutent: Total International
- 160.00
- 314.00
- 546.00
- 597.00
- 653.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Sutent: United States
- 20.00
- 33.00
- 127.00
- 223.00
- 283.00
- Revenue - Geographic (GEOR)
- Revenues: Primary Care: Premarin family: Total International
- 36.00
- 36.00
- 38.00
- 42.00
- 44.00
- Revenue - Geographic (GEOR)
- Revenues: Primary Care: Premarin family: United States
- 361.00
- 420.00
- 525.00
- 637.00
- 690.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Prevnar family: Total International
- 2,236.00
- 2,305.00
- 2,571.00
- 2,920.00
- 2,638.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Prevnar family: United states
- 4,204.00
- 4,032.00
- 2,701.00
- 2,930.00
- 3,209.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Refacto AF/Xyntha: Total International
- 171.00
- 180.00
- 240.00
- 295.00
- 333.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Refacto AF/Xynth: United States
- 59.00
- 59.00
- 64.00
- 74.00
- 92.00
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care: Sulperazon: Total International
- 757.00
- 786.00
- 683.00
- 618.00
- 684.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Somavert: Total International
- 158.00
- 157.00
- 179.00
- 618.00
- 159.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Somavert: United States
- 109.00
- 111.00
- 98.00
- 0.00
- 105.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Inlyta: United States
- 642.00
- 618.00
- 599.00
- 523.00
- 295.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Inlyta: Total International
- 394.00
- 385.00
- 403.00
- 264.00
- 182.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Xalkori: Total International
- 274.00
- 361.00
- 391.00
- 406.00
- 381.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Xeljanz: United States
- 1,154.00
- 1,129.00
- 1,647.00
- 1,706.00
- 1,636.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Xeljanz: Total International
- 549.00
- 668.00
- 808.00
- 731.00
- 606.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Xalkor: United States
- 100.00
- 105.00
- 102.00
- 138.00
- 149.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Ibrance; United States
- 3,151.00
- 3,370.00
- 3,418.00
- 3,634.00
- 3,250.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Ibrance: Total International
- 1,602.00
- 1,751.00
- 2,019.00
- 1,758.00
- 1,710.00
- Revenue - Geographic (GEOR)
- Revenues: FSME-IMMUN/TicoVac - US
- 3.00
- 2.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-All Other Oncology - US
- 300.00
- 216.00
- 129.00
- 91.00
- 219.00
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-All Other Oncology - ROW
- 133.00
- 140.00
- 109.00
- 46.00
- 251.00
- Revenue - Geographic (GEOR)
- Revenue: FSME/IMMUN-TicoVac: ROW
- 265.00
- 198.00
- 185.00
- 196.00
- --
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Inflectra: United States
- 257.00
- 289.00
- 385.00
- 341.00
- 300.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Inflectra: Total International
- 233.00
- 243.00
- 272.00
- 318.00
- 325.00
- Revenue - Geographic (GEOR)
- Revenues: Primary Care: Eliquis alliance revenues and direct sales: Total International
- 2,519.00
- 2,658.00
- 2,810.00
- 2,260.00
- 1,877.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Bosulif: United States
- 444.00
- 375.00
- 354.00
- 304.00
- 243.00
- Revenue - Geographic (GEOR)
- Revenues: Oncology: Bosulif: Total International
- 200.00
- 200.00
- 186.00
- 146.00
- 122.00
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology - US
- 7,627.00
- 7,921.00
- 7,736.00
- 7,048.00
- 5,591.00
- Revenue - Geographic (GEOR)
- Revenue: Pharmaceutical-Oncology - ROW
- 4,000.00
- 4,210.00
- 4,597.00
- 3,819.00
- 3,422.00
- Revenue - Geographic (GEOR)
- Pfizer Biopharma: US
- 26,698.00
- 42,083.00
- 29,221.00
- 21,055.00
- --
- Revenue - Geographic (GEOR)
- Pfizer Biopharma: ROW
- 30,488.00
- 56,905.00
- 50,336.00
- 19,670.00
- --
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Vyndaqel family: United States
- 1,863.00
- 1,245.00
- 909.00
- 613.00
- 191.00
- Revenue - Geographic (GEOR)
- Revenues: Specialty Care: Vyndaqel family: Total International
- 1,458.00
- 1,202.00
- 1,106.00
- 675.00
- 282.00
- Revenue - Geographic (GEOR)
- Revenue: Primary Care: Nimenrix: Total International
- 179.00
- 268.00
- 48.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care: Oxbryta: United States
- 323.00
- 72.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care: Oxbryta: Total International
- 5.00
- 0.00
- 0.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Pharmaceutical: Primary Care - All Other Primary Care - US
- 315.00
- 340.00
- 45.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenues: Pharmaceutical: Primary Care - All Other Primary Care - ROW
- 1,462.00
- 1,592.00
- 433.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - Cibinqo -US
- 46.00
- 11.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - Cibinqo -International
- 81.00
- 16.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - All other Anti-infectives-US
- 258.00
- 317.00
- 511.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - All other Anti-infectives-International
- 834.00
- 854.00
- 1,324.00
- --
- --
- Revenue - Geographic (GEOR)
- Revenue: Specialty Care - All other Specialty Care-US
- 1,280.00
- 1,351.00
- 1,608.00
- --
- --